Merck Acquires Rosetta Inpharmatics for $620 Million in Stock | GenomeWeb

NEW YORK, May 11 – Merck has agreed to acquire Rosetta Inpharmatics in a stock-for-stock transaction worth $620 million, the companies said Friday.

The tax-free reorganization will swap each share of Rosetta stock for 0.2352 shares of Merck stock, giving a value of $18 per share of Rosetta stock, an 82 percent premium on Thursday’s closing price.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.